continue on current dual boosted PI — Competitive Intelligence Brief

continue on current dual boosted PI (continue on current dual boosted PI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor (PI) combination with pharmacokinetic booster. Area: Infectious Disease / Virology.

marketed Protease inhibitor (PI) combination with pharmacokinetic booster HIV protease Infectious Disease / Virology Small molecule

Target snapshot

continue on current dual boosted PI (continue on current dual boosted PI) — Community Research Initiative of New England. Dual-boosted protease inhibitors block HIV protease to prevent viral replication and reduce viral load in HIV-infected patients.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
continue on current dual boosted PI TARGET	continue on current dual boosted PI	Community Research Initiative of New England	marketed	Protease inhibitor (PI) combination with pharmacokinetic booster	HIV protease
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
Darunavir, Ritonavir and Etravirine	Darunavir, Ritonavir and Etravirine	Imperial College London	marketed	Antiretroviral combination (protease inhibitor + NNRTI)	HIV protease, HIV reverse transcriptase
Telzir®	Telzir®	ViiV Healthcare	marketed	HIV protease inhibitor	HIV protease
TMC114/ritonavir	TMC114/ritonavir	Janssen-Cilag Ltd.	marketed	HIV protease inhibitor	HIV protease
Ritonavir (heat-stable)	Ritonavir (heat-stable)	Bristol-Myers Squibb	marketed	HIV protease inhibitor	HIV protease
Darunavir, Ritonavir and Rilpivirine	Darunavir, Ritonavir and Rilpivirine	St Stephens Aids Trust	marketed	Antiretroviral combination (protease inhibitor + NNRTI)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor (PI) combination with pharmacokinetic booster class)

1. Community Research Initiative of New England · 1 drug in this class